MCIDAS and metabolic dysfunction-associated steatohepatitis: Therefore, it is important in future studies to clarify whether benign liver steatosis is also associated with a reduction in MC-I activity in order to validate the effectiveness of 18F-BCPP-BF for the diagnosis of NASH at an early phase.